je.st
news
Novo Nordisk buys rights to Caisson's drug-extending biotech
2014-03-18 23:01:17| Biotech - Topix.net
HEPtune, which conjugates the polymer heparosan to a drug to prolong its half-life, will be licensed to Novo Nordisk exclusively for insulin products, and non-exclusively for delivery of other therapies including human growth hormones and treatments for obesity and inflammatory diseases.
Tags: rights
novo
biotech
buys
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||